Preclinical remodeling of human prostate cancer through the PTEN/AKT pathway

Advances in Urology

Volumn , Issue , 2012, Pages

  De Velasco, Marco A ^a   Uemura, Hirotsugu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858245660     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/419348     Document Type: Review

References (131)

1. Huggins C., Hodges C. V., Estrogen and of androgen injection on serum phosphatases studies on prostatic cancer. I. The effect of castration, of in metastatic carcinoma of the prostate Cancer Research 1941 1 293 297
2. De Bono J. S., Logothetis C. J., Molina A., Abiraterone and increased survival in metastatic prostate cancer The New England Journal of Medicine 2011 364 21 1995 2005
3. Tannock I. F., Osoba D., Stockler M. R., Ernst D. S., Neville A. J., Moore M. J., Armitage G. R., Wilson J. J., Venner P. M., Coppin C. M. L., Murphy K. C., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points Journal of Clinical Oncology 1996 14 6 1756 1764 (Pubitemid 26185452)
4. Beltran H., Beer T. M., Carducci M. A., De Bono J., Gleave M., Hussain M., Kelly W. K., Saad F., Sternberg C., Tagawa S. T., Tannock I. F., New therapies for castration-resistant prostate cancer: efficacy and safety European Urology 2011 60 2 279 290
5. Tannock I. F., De Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer The New England Journal of Medicine 2004 351 15 1502 1512 (Pubitemid 39315317)
6. Berthold D. R., Pond G. R., Soban F., De Wit R., Eisenberger M., Tannock I. F., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study Journal of Clinical Oncology 2008 26 2 242 245
7. de Bono J. S., Oudard S., Ozguroglu M., Hansen S., MacHiels J. P., Kocak I., Gravis G., Bodrogi I., MacKenzie M. J., Shen L., Roessner M., Gupta S., Sartor A. O., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial The Lancet 2010 376 9747 1147 1154
8. Kwitkowski V. E., Prowell T. M., Ibrahim A., Farrell A. T., Justice R., Mitchell S. S., Sridhara R., Pazdur R., FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma Oncologist 2010 15 4 428 435
9. Bukowski R. M., Yasothan U., Kirkpatrick P., Pazopanib Nature Reviews Drug Discovery 2010 9 1 17 18
10. Joensuu H., Dematteo R. P., The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy Annual Review of Medicine 2011 63 10.1 10.12
11. Tkaczuk K. H. R., Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer Clinical Therapeutics 2009 31 2 2273 2289
12. Burris H., Rocha-Lima C., New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways Oncologist 2008 13 3 289 298 (Pubitemid 351679904)
13. Eng C., The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development Oncologist 2010 15 1 73 84
14. Cataldo V. D., Gibbons D. L., Pérez-Soler R., Treatment of nonsmall-cell lung cancer with erlotinib or gefitinib The New England Journal of Medicine 2011 364 10 947 955
15. Gonzalez-Angulo A. M., Hennessy B. T., Mills G. B., Future of personalized medicine in oncology: a systems biology approach Journal of Clinical Oncology 2010 28 16 2777 2783
16. Jeet V., Russell P. J., Khatri A., Modeling prostate cancer: a perspective on transgenic mouse models Cancer and Metastasis Reviews 2010 29 1 123 142
17. Navone N. M., Logothetis C. J., Von Eschenbach A. C., Troncoso P., Model systems of prostate cancer: uses and limitations Cancer and Metastasis Reviews 1999 17 4 361 371 (Pubitemid 29331786)
18. Van Weerden W. M., Bangma C., de Wit R., Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer British Journal of Cancer 2009 100 1 13 18
19. Van Weerden W. M., Romijn J. C., Use of nude mouse xenograft models in prostate cancer research Prostate 2000 43 4 263 271 (Pubitemid 30367961)
20. Kola I., Landis J., Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 2004 3 8 711 715 (Pubitemid 39173511)
21. Booth B., Glassman R., Ma P., Oncology's trials. Market indicators Nature Reviews Drug Discovery 2003 2 8 609 610 (Pubitemid 37361763)
22. Greenberg N. M., DeMayo F., Finegold M. J., Medina D., Tilley W. D., Aspinall J. O., Cunha G. R., Donjacour A. A., Matusik R. J., Rosen J. M., Prostate cancer in a transgenic mouse Proceedings of the National Academy of Sciences of the United States of America 1995 92 8 3439 3443
23. Mimeault M., Batra S. K., Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells Biochimica et Biophysica Acta 2011 1816 1 25 37
24. Blanco-Aparicio C., Renner O., Leal J. F. M., Carnero A., PTEN, more than the AKT pathway Carcinogenesis 2007 28 7 1379 1386 (Pubitemid 47243536)
25. Maehama T., Dixon J. E., The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate The Journal of Biological Chemistry 1998 273 22 13375 13378 (Pubitemid 28268370)
26. Vivanco I., Sawyers C. L., The phosphatidylinositol 3-kinase-AKT pathway in human cancer Nature Reviews Cancer 2002 2 7 489 501 (Pubitemid 37328931)
27. Kandel E. S., Hay N., The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB Experimental Cell Research 1999 253 1 210 229
28. Yap T. A., Garrett M. D., Walton M. I., Raynaud F., de Bono J. S., Workman P., Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises Current Opinion in Pharmacology 2008 8 4 393 412
29. Suzuki H., Freije D., Nusskern D. R., Okami K., Cairns P., Sidransky D., Isaacs W. B., Bova G. S., Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues Cancer Research 1998 58 2 204 209 (Pubitemid 28047054)
30. Yoshimoto M., Cunha I. W., Coudry R. A., Fonseca F. P., Torres C. H., Soares F. A., Squire J. A., FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome British Journal of Cancer 2007 97 5 678 685 (Pubitemid 47339893)
31. Sircar K., Yoshimoto M., Monzon F. A., Koumakpayi I. H., Katz R. L., Khanna A., Alvarez K., Chen G., Darnel A. D., Aprikian A. G., Saad F., Bismar T. A., Squire J. A., PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer Journal of Pathology 2009 218 4 505 513
32. McCall P., Witton C. J., Grimsley S., Nielsen K. V., Edwards J., Is PTEN loss associated with clinical outcome measures in human prostate cancer? British Journal of Cancer 2008 99 8 1296 1301
33. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J. G., Jen J., Isaacs W. B., Bova G. S., Sidransky D., Frequent inactivation of PTEN/MMAC1 in primary prostate cancer Cancer Research 1997 57 22 4997 5000 (Pubitemid 27498107)
34. Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., Said J. W., Isaacs W. B., Sawyers C. L., Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression Proceedings of the National Academy of Sciences of the United States of America 1998 95 9 5246 5250 (Pubitemid 28208583)
35. Taylor B. S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B. S., Arora V. K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J. E., Wilson M., Socci N. D., Lash A. E., Heguy A., Eastham J. A., Scher H. I., Reuter V. E., Scardino P. T., Sander C., Sawyers C. L., Gerald W. L., Integrative genomic profiling of human prostate cancer Cancer Cell 2010 18 1 11 22
36. Massard C., Fizazi K., Targeting continued androgen receptor signaling in prostate cancer Clinical Cancer Research 2011 17 12 3876 3883
37. Ha S., Ruoff R., Kahoud N., Franke T. F., Logan S. K., Androgen receptor levels are upregulated by Akt in prostate cancer Endocrine-Related Cancer 2011 18 2 245 255
38. Wen Y., Hu M. C. T., Makino K., Spohn B., Bartholomeusz G., Yan D. H., Hung M. C., HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway Cancer Research 2000 60 24 6841 6845 (Pubitemid 32059149)
39. Heinlein C. A., Chang C., Androgen receptor in prostate cancer Endocrine Reviews 2004 25 2 276 308 (Pubitemid 38501396)
40. Roudier M. P., True L. D., Higano C. S., Vesselle H., Ellis W., Lange P., Vessella R. L., Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone Human Pathology 2003 34 7 646 653 (Pubitemid 36875509)
41. Shah R. B., Mehra R., Chinnaiyan A. M., Shen R., Ghosh D., Zhou M., MacVicar G. R., Varambally S., Harwood J., Bismar T. A., Kim R., Rubin M. A., Pienta K. J., Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program Cancer Research 2004 64 24 9209 9216 (Pubitemid 39665537)
42. Marques R. B., Dits N. F., Erkens-Schulze S., van IJcken W. F. J., van Weerden W. M., Jenster G., Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines PLoS ONE 2011 6 8, article e23144
43. Tilley W. D., Buchanan G., Hickey T. E., Bentel J. M., Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence Clinical Cancer Research 1996 2 2 277 285 (Pubitemid 26074615)
44. Carver B., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., Arora V., Le C., Koutcher J., Scher H., Scardino P., Rosen N., Sawyers C., Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 2011 19 5 575 586
45. Mulholland D., Tran L., Li Y., Cai H., Morim A., Wang S., Plaisier S., Garraway I., Huang J., Graeber T., Wu H., Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth Cancer Cell 2011 19 6 792 804
46. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P. P., Pten is essential for embryonic development and tumour suppression Nature Genetics 1998 19 4 348 355 (Pubitemid 28357906)
47. Podsypanina K., Ellenson L. H., Nemes A., Gu J., Tamura M., Yamada K. M., Cordon-Cardo C., Catoretti G., Fisher P. E., Parsons R., Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems Proceedings of the National Academy of Sciences of the United States of America 1999 96 4 1563 1568 (Pubitemid 29098491)
48. Dong J. T., Chromosomal deletions and tumor suppressor genes in prostate cancer Cancer and Metastasis Reviews 2001 20 3-4 173 193
49. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., Ittmann M., Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11563 11568 (Pubitemid 32928768)
50. You M. J., Castrillon D. H., Bastian B. C., O'Hagan R. C., Bosenberg M. W., Parsons R., Chin L., DePinho R. A., Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice Proceedings of the National Academy of Sciences of the United States of America 2002 99 3 1455 1460 (Pubitemid 34136514)
51. Abate-Shen C., Banach-Petrosky W. A., Sun X., Economides K. D., Desai N., Gregg J. P., Borowsky A. D., Cardiff R. D., Shen M. M., Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases Cancer Research 2003 63 14 3886 3890 (Pubitemid 36917899)
52. Kim M. J., Cardiff R. D., Desai N., Banach-Petrosky W. A., Parsons R., Shen M. M., Abate-Shen C., Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis Proceedings of the National Academy of Sciences of the United States of America 2002 99 5 2884 2889 (Pubitemid 34240555)
53. Gao H., Ouyang X., Banach-Petrosky W. A., Shen M. M., Abate-Shen C., Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice Cancer Research 2006 66 16 7929 7933 (Pubitemid 44299155)
54. Chen M. L., Xu P. Z., Peng X. D., Chen W. S., Guzman G., Yang X., Di Cristofano A., Pandolfi P. P., Hay N., The deficiency of Akt1 is sufficient to suppress tumor development in Pten +/- mice Genes and Development 2006 20 12 1569 1574 (Pubitemid 43901096)
55. Carver B. S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., Alimonti A., Nardella C., Varmeh S., Scardino P. T., Cordon-Cardo C., Gerald W., Pandolfi P. P., Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nature Genetics 2009 41 5 619 624
56. Blando J. M., Carbajal S., Abel E., Beltran L., Conti C., Fischer S., Di Giovanni J., Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice Neoplasia 2011 13 3 254 265
57. Majumder P. K., Yeh J. J., George D. J., Febbo P. G., Kum J., Xue Q., Bikoff R., Ma H., Kantoff P. W., Golub T. R., Loda M., Sellers W. R., Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model Proceedings of the National Academy of Sciences of the United States of America 2003 100 13 7841 7846 (Pubitemid 36760057)
58. Xu P. Z., Chen M. L., Jeon S. M., Peng X. d., Hay N., The effect Akt2 deletion on tumor development in Pten +/- mice Oncogene 2012 31 518 526
59. Abate-Shen C., Shen M. M., Molecular genetics of prostate cancer Genes and Development 2000 14 19 2410 2434
60. Reynolds M. A., Molecular alterations in prostate cancer Cancer Letters 2008 271 1 13 24
61. Osman I., Drobnjak M., Fazzari M., Ferrara J., Scher H. I., Cordon-Cardo C., Inactivation of the p53 pathway in prostate cancer: impact on tumor progression Clinical Cancer Research 1999 5 8 2082 2088 (Pubitemid 29399262)
62. Cooney K. A., Wetzel J. C., Merajver S. D., Macoska J. A., Singleton T. P., Wojno K. J., Distinct regions of allelic loss on 13q in prostate cancer Cancer Research 1996 56 5 1142 1145 (Pubitemid 26065413)
63. Senz Robles M. T., Pipas J. M., T antigen transgenic mouse models Seminars in Cancer Biology 2009 19 4 229 235
64. Sharpless N. E., INK4a/ARF: a multifunctional tumor suppressor locus Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 2005 576 1-2 22 38 (Pubitemid 40982680)
65. Guo Y., Sklar G. N., Borkowski A., Kyprianou N., Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade Clinical Cancer Research 1997 3 12 2269 2274 (Pubitemid 28133145)
66. Dong J. T., Prevalent mutations in prostate cancer Journal of Cellular Biochemistry 2006 97 3 433 447
67. Cordon-Cardo C., Koff A., Drobnjak M., Capodieci P., Osman I., Millard S. S., Gaudin P. B., Fazzari M., Zhang Z. F., Massague J., Scher H. I., Distinct altered patterns of p27(KIP1) gene expression in benign prostatic hyperplasia and prostatic carcinoma Journal of the National Cancer Institute 1998 90 17 1284 1291 (Pubitemid 28433473)
68. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., P Pandolfi P., Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse Nature Genetics 2001 27 2 222 224 (Pubitemid 32157454)
69. Bieberich C. J., Fujita K., He W. W., Jaj G., Prostate-specific and androgen-dependent expression of a novel homeobox gene The Journal of Biological Chemistry 1996 271 50 31779 31782 (Pubitemid 26422192)
70. Voeller H. J., Augustus M., Madike V., Bova G. S., Carter K. C., Gelmann E. P., Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers Cancer Research 1997 57 20 4455 4459 (Pubitemid 27441043)
71. Bowen C., Bubendorf L., Voeller H. J., Slack R., Willi N., Sauter G., Gasser T. C., Koivisto P., Lack E. E., Kononen J., Kallioniemi O. P., Gelmann E. P., Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression Cancer Research 2000 60 21 6111 6115
72. Bhatia-Gaur R., Donjacour A. A., Sciavolino P. J., Kim M., Desai N., Young P., Norton C. R., Gridley T., Cardiff R. D., Cunha G. R., Abate-Shen C., Shen M. M., Roles for Nkx3.1 in prostate development and cancer Genes and Development 1999 13 8 966 977 (Pubitemid 29200980)
73. Abdulkadir S. A., Magee J. A., Peters T. J., Kaleem Z., Naughton C. K., Humphrey P. A., Milbrandt J., Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia Molecular and Cellular Biology 2002 22 5 1495 1503 (Pubitemid 34150785)
74. Tomlins S. A., Rhodes D. R., Perner S., Dhanasekaran S. M., Mehra R., Sun X. W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J. E., Shah R. B., Pienta K. J., Rubin M. A., Chinnaiyan A. M., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 2005 310 5748 644 648 (Pubitemid 41528150)
75. Tomlins S. A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B. E., Cao Q., Prensner J. R., Rubin M. A., Shah R. B., Mehra R., Chinnaiyan A. M., Role of the TMPRSS2-ERG gene fusion in prostate cancer Neoplasia 2008 10 2 177 188 (Pubitemid 351240884)
76. FitzGerald L. M., Agalliu I., Johnson K., Miller M. A., Kwon E. M., Hurtado-Coll A., Fazli L., Rajput A. B., Gleave M. E., Cox M. E., Ostrander E. A., Stanford J. L., Huntsman D. G., Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer BMC Cancer 2008 8, article 230
77. Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., Lisanti M. P., Zellweger T., Alanen K., Mirtti T., Visakorpi T., Bubendorf L., Nevalainen M. T., Stat3 promotes metastatic progression of prostate cancer American Journal of Pathology 2008 172 6 1717 1728 (Pubitemid 351793362)
78. Sauer B., Henderson N., Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1 Proceedings of the National Academy of Sciences of the United States of America 1988 85 14 5166 5170
79. Nagy A., Cre recombinase: the universal reagent for genome tailoring Genesis 2000 26 2 99 109 (Pubitemid 30158089)
80. Utomo A. R. H., Nikitin A. Y., Lee W. H., Temporal, spatial of and cell type-specified control of cre-mediated DNA recombination in transgenic mice Nature Biotechnology 1999 17 11 1091 1096 (Pubitemid 29533548)
81. Valkenburg K. C., Williams B. O., Mouse models of prostate cancer Prostate Cancer 2011 2011 1 22
82. Winter S. F., Cooper A. B., Greenberg N. M., Models of metastatic prostate cancer: a transgenic perspective Prostate Cancer and Prostatic Diseases 2003 6 3 204 211 (Pubitemid 37185147)
83. Ahmad I., Sansom O. J., Leung H. Y., Advances in mouse models of prostate cancer Expert Reviews in Molecular Medicine 2008 10, article 16
84. Trotman L. C., Niki M., Dotan Z. A., Koutcher J. A., Di Cristofano A., Xiao A., Khoo A. S., Roy-Burman P., Greenberg N. M., Van Dyke T., Cordon-Cardo C., Pandolfi P. P., Pten dose dictates cancer progression in the prostate PLoS Biology 2003 1 3 385 396
85. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G. V., Li G., Roy-Burman P., Nelson P. S., Liu X., Wu H., Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 2003 4 3 209 221 (Pubitemid 37163835)
86. Ma X., Ziel-Van Der Made A. C., Autar B., Van Der Korput H. A., Vermeij M., Van Duijn P., Cleutjens K. B., De Krijger R., Krimpenfort P., Berns A., Van Der Kwast T. H., Trapman J., Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis Cancer Research 2005 65 13 5730 5739 (Pubitemid 40911176)
87. Zhong C., Saribekyan G., Liao C. P., Cohen M. B., Roy-Burman P., Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis Cancer Research 2006 66 4 2188 2194
88. Chen Z., Trotman L. C., Shaffer D., Lin H. K., Dotan Z. A., Niki M., Koutcher J. A., Scher H. I., Ludwig T., Gerald W., Cordon-Cardo C., Pandolfi P. P., Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis Nature 2005 436 7051 725 730 (Pubitemid 41117277)
89. Backman S. A., Ghazarian D., So K., Sanchez O., Wagner K. U., Hennighausen L., Suzuki A., Tsao M. S., Chapman W. B., Stambolic V., Mak T. W., Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten Proceedings of the National Academy of Sciences of the United States of America 2004 101 6 1725 1730 (Pubitemid 38234221)
90. Ratnacaram C. K., Teletin M., Jiang M., Meng X., Chambon P., Metzger D., Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma Proceedings of the National Academy of Sciences of the United States of America 2008 105 7 2521 2526 (Pubitemid 351520546)
91. Wang X., Kruithof-de Julio M. K. D., Economides K. D., Walker D., Yu H., Halili M. V., Hu Y. P., Price S. M., Abate-Shen C., Shen M. M., A luminal epithelial stem cell that is a cell of origin for prostate cancer Nature 2009 461 7263 495 500
92. Marino S., Krimpenfort P., Leung C., van der Korput H. A. G. M., Trapman J., Camenisch I., Berns A., Brandner S., PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum Development 2002 129 14 3513 3522
93. Suzuki A., Yamaguchi M. T., Ohteki T., Sasaki T., Kaisho T., Kimura Y., Yoshida R., Wakeham A., Higuchi T., Fukumoto M., Tsubata T., Ohashi P. S., Koyasu S., Penninger J. M., Nakano T., Mak T. W., T cell-specific loss of Pten leads to defects in central and peripheral tolerance Immunity 2001 14 5 523 534 (Pubitemid 32520864)
94. Lesche R., Groszer M., Gao J., Wang Y., Messing A., Sun H., Liu X., Wu H., Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene Genesis 2002 32 2 148 149 (Pubitemid 34211723)
95. De Velasco M. A., Tanaka M., Tomioka A., Characterization of a prostate-specific conditional Pten-mutant mouse model of prostate cancer. In preparation
96. Berquin I. M., Min Y., Wu R., Wu H., Chen Y. Q., Expression signature of the mouse prostate The Journal of Biological Chemistry 2005 280 43 36442 36451 (Pubitemid 41633918)
97. Shappell S. B., Thomas G. V., Roberts R. L., Herbert R., Ittmann M. M., Rubin M. A., Humphrey P. A., Sundberg J. P., Rozengurt N., Barrios R., Ward J. M., Cardiff R. D., Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee Cancer Research 2004 64 6 2270 2305 (Pubitemid 38339483)
98. Imasato Y., Onita T., Moussa M., Sakai H., Chan F. L., Koropatnick J., Chin J. L., Xuan J. W., Rodent PSP94 gene expression is more specific to the dorsolateral prostate and less sensitive to androgen ablation than probasin Endocrinology 2001 142 5 2138 2146 (Pubitemid 32405974)
99. Amato R. J., Jac J., Mohammad T., Saxena S., Pilot study of rapamycin in patients with hormone-refractory prostate cancer Clinical Genitourinary Cancer 2008 6 2 97 102
100. Dowling R. J. O., Topisirovic I., Fonseca B. D., Sonenberg N., Dissecting the role of mTOR: lessons from mTOR inhibitors Biochimica et Biophysica Acta-Proteins and Proteomics 2010 1804 3 433 439
101. Sarker D., Reid A. H. M., Yap T. A., De Bono J. S., Targeting the PI3K/AKT pathway for the treatment of prostate cancer Clinical Cancer Research 2009 15 15 4799 4805
102. Manning B. D., Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis Journal of Cell Biology 2004 167 3 399 403 (Pubitemid 39489047)
103. Park S., Zhao D., Hatanpaa K. J., Mickey B. E., Saha D., Boothman D. A., Story M. D., Wong E. T., Burma S., Georgescu M. M., Rangnekar V. M., Chauncey S. S., Habib A. A., RIP1 activates PI3K-Akt via a dual mechanism involving NF- B-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN Cancer Research 2009 69 10 4107 4111
104. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A. T., Thomas G., Kozma S. C., Papa A., Nardella C., Cantley L. C., Baselga J., Pandolfi P. P., Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer Journal of Clinical Investigation 2008 118 9 3065 3074
105. Kinkade C. W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T. H., Gao H., Sun Y., Ouyang X., Gerald W. L., Cordon-Cardo C., Abate-Shen C., Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model Journal of Clinical Investigation 2008 118 9 3051 3064
106. Gioeli D., Mandell J. W., Petroni G. R., Activation of mitogen-activated protein kinase associated with prostate cancer progression advances in brief activation of mitogen-activated protein kinase associated with prostate Cancer Research 1999 59 279 284 (Pubitemid 29048852)
107. Zellweger T., Ninck C., Bloch M., Mirlacher M., Koivisto P. A., Helin H. J., Mihatsch M. J., Gasser T. C., Bubendorf L., Expression patterns of potential therapeutic targets in prostate cancer International Journal of Cancer 2005 113 4 619 628 (Pubitemid 40038739)
108. Lorenzo G. D., Tortora G., D'Armiento F. P., De Rosa G., Staibano S., Autorino R., D'Armiento M., De Laurentiis M., De Placido S., Catalano G., Bianco A. R., Ciardiello F., Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer Clinical Cancer Research 2002 8 11 3438 3444 (Pubitemid 35340719)
109. Weber M. J., Gioeli D., Ras signaling in prostate cancer progression Journal of Cellular Biochemistry 2004 91 1 13 25
110. Keller E. T., Fu Z., Yeung K., Brennan M., Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene Cancer Letters 2004 207 2 131 137 (Pubitemid 38457033)
111. Steelman L. S., Bertrand F. E., McCubrey J. A., The complexity of PTEN: mutation, marker and potential target for therapeutic intervention Expert Opinion on Therapeutic Targets 2004 8 6 537 550 (Pubitemid 40028365)
112. Ghosh P. M., Malik S. N., Bedolla R. G., Wang Y., Mikhailova M., Prihoda T. J., Troyer D. A., Kreisberg J. I., Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocrine-Related Cancer 2005 12 1 119 134 (Pubitemid 40477093)
113. McCubrey J. A., Steelman L. S., Abrams S. L., Lee J. T., Chang F., Bertrand F. E., Navolanic P. M., Terrian D. M., Franklin R. A., D'Assoro A. B., Salisbury J. L., Mazzarino M. C., Stivala F., Libra M., Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Advances in Enzyme Regulation 2006 46 1 249 279 (Pubitemid 44301348)
114. Grant S., Cotargeting survival signaling pathways in cancer Journal of Clinical Investigation 2008 118 9 3003 3006
115. Silver D. L., Montell D. J., Paracrine signaling through the JAK/STAT pathway activates invasive behavior of ovarian epithelial cells in drosophila Cell 2001 107 7 831 841 (Pubitemid 34084975)
116. Leeman R. J., Lui V. W. Y., Grandis J. R., STAT3 as a therapeutic target in head and neck cancer Expert Opinion on Biological Therapy 2006 6 3 231 241 (Pubitemid 43344743)
117. Turkson J., Jove R., STAT proteins: novel molecular targets for cancer drug discovery Oncogene 2000 19 56 6613 6626 (Pubitemid 32197700)
118. Buettner R., Mora L. B., Jove R., Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention Clinical Cancer Research 2002 8 4 945 954 (Pubitemid 35177340)
119. Niu G., Wright K. L., Ma Y., Wright G. M., Huang M., Irby R., Briggs J., Karras J., Cress W. D., Pardoll D., Jove R., Chen J., Yu H., Role of Stat3 in regulating p53 expression and function Molecular and Cellular Biology 2005 25 17 7432 7440 (Pubitemid 41170107)
120. Mora L. B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., Bowman T., Falcone R., Fairclough R., Cantor A., Muro-Cacho C., Livingston S., Karras J., Pow-Sang J., Jove R., Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells Cancer Research 2002 62 22 6659 6666 (Pubitemid 35364135)
121. Yu H., Jove R., The stats of cancerNew molecular targets come of age Nature Reviews Cancer 2004 4 2 97 105 (Pubitemid 38198738)
122. Lou W., Ni Z., Dyer K., Tweardy D. J., Gao A. C., Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway Prostate 2000 42 3 239 242 (Pubitemid 30080423)
123. Wen Z., Zhong Z., Darnell J. E., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation Cell 1995 82 2 241 250
124. Yang L., Wang L., Lin H. K., Kan P. Y., Xie S., Tsai M. Y., Wang P. H., Chen Y. T., Chang C., Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells Biochemical and Biophysical Research Communications 2003 305 3 462 469 (Pubitemid 36579252)
125. Tam L., McGlynn L. M., Traynor P., Mukherjee R., Bartlett J. M. S., Edwards J., Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer British Journal of Cancer 2007 97 3 378 383 (Pubitemid 47196744)
126. Cutler R. L., Liu L., Damen J. E., Krystal G., Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hemopoietic cells The Journal of Biological Chemistry 1993 268 29 21463 21465 (Pubitemid 23320626)
127. Qiu Y., Ravi L., Kung H. J., Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells Nature 1998 393 6680 83 85 (Pubitemid 28240259)
128. Repsilber D., Kern S., Telaar A., Walzl G., Black G. F., Selbig J., Parida S. K., Kaufmann S. H. E., Jacobsen M., Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach BMC Bioinformatics 2010 11, article 27
129. Lhdesmki H., Shmulevich I., Dunmire V., Yli-Harja O., Zhang W., In silico microdissection of microarray data from heterogeneous cell populations BMC Bioinformatics 2005 6, article 54
130. Schiess R., Wollscheid B., Aebersold R., Targeted proteomic strategy for clinical biomarker discovery Molecular Oncology 2009 3 1 33 44
131. Chin L., Gray J. W., Translating insights from the cancer genome into clinical practice Nature 2008 452 7187 553 563 (Pubitemid 351483369)